Aromatase inhibitors or fulvestrant in combination with a cyclin-dependent kinase inhibitor CDK4/6, e.g., palbocyclib or alone—tamoxifen, aromatase inhibitors, or high doses (500 mg i.m.)of fulvestrant are used for hormonal treatment in patients with advanced breast cancer [5,6,7]. This evidence concerns the gene CYP19A1 and breast carcinoma.